Stockholm, 2020-02-25

Press release

QuiaPEG shows Proof-of-Concept in preclinical efficacy study with QPG-1029

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today demonstrated Proof-of-Concept after positive results from a preclinical efficacy study in the QPG-1029 research project (pegylated liraglutide), for the treatment of type 2 diabetes and obesity.

QuiaPEG has conducted a preclinical study to evaluate the efficacy of the company's candidate substance QPG-1029 (pegylated liraglutide) for the treatment of type 2 diabetes and obesity. The study was conducted by Gubra ApS, a company specializing in pharmacological research in diabetes and other metabolic diseases and compared QPG-1029 with diabetes drugs liraglutide and semaglutide regarding the effect on food intake and weight in healthy rats (n=56).

After subcutaneous injection of each substance, the animals were followed for a week with continuous measurement of food intake and daily weighing. Compared to a control group without active treatment, all treatment groups showed clear effects on food intake (reductions between 63 and 78 percent) and weight during the first 24 hours of the study. QPG-1029 resulted in a dose-dependent extension of the treatment effect. Between 24 and 48 hours, the reduction in food intake was 39 and 78 percent, respectively, in the two groups treated with QPG-1029, while the groups that were treated with liraglutide or semaglutide displayed reductions between 22 and 42 percent. In contrast to the groups treated with liraglutide and semaglutide, the groups treated with QPG-1029 maintained a statistically significant reduction in weight gain compared to the control animals until the end of the study. The study results show that QuiaPEG's goal of extending the dosing interval for treatment with liraglutide from one day to one week is quite possible.

"This study unequivocally shows that QPG-1029 and QuiaPEG's Uni-Qleaver® technology platform work as intended and validate our treatment concept. That the extension of the treatment effect was more pronounced with QPG-1029 compared to semaglutide, which is dosed weekly, came as a positive surprise," said Cecilia Kemi, chief operating officer.

"The results mean the technical risk with our platform has significantly decreased, while the opportunities to reach licensing agreements in the future have increased considerably," says Marcus Bosson, chief executive officer.

The results mean QuiaPEG will continue the QPG-1029 development program. After evaluating the treatment effect in the Proof-of-Concept study, pharmacokinetic studies with repeated dosing and toxicology and safety studies will be carried out before the clinical program can start. In parallel, the development of the production process and formulation and stability studies will continue.

Liraglutide is an approved drug with annual sales of approximately $4 billion and the basic patent expires in 2022. Liraglutide was developed by Novo Nordisk and is sold under the Victoza and Saxenda brands within the indications type 2 diabetes and obesity.

More than half a billion individuals globally are affected by diabetes, most of whom have type 2 diabetes. The market for diabetes drugs was estimated at $31 billion in 2015 (GlobalData) and annual growth is estimated to be around 6.5 percent until 2025.

For more information, please contact:
Marcus Bosson, Managing Director
Tel: +46-70-693 1253
Email: marcus.bosson@quiapeg.com

This information is information that QuiaPEG Pharmaceuticals Holding AB (publ) is obliged to make public pursuant tothe EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on February 25, 2020.

About QuiaPEG
QuiaPEG Pharmaceuticals Holding AB (publ) is a drug development company based on a patented so called drug delivery platform, Uni-Qleaver®. The company develops improved and patentable forms of drugs under development or which have already been approved by pharmaceutical authorities. These refined and better forms of pharmaceuticals are based on the company's unique and patented technology platform. The company is listed on Spotlight (ticker: QUIA).

About Gubra
Founded in 2008, Gubra is a privately held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in five main focus areas: diabetes, NASH, obesity, CVD and CKD. Gubra experts covers a number of pre-clinical disciplines: *in vivo* pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and *ex vivo* assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers by combining cutting-edge technology with accumulated experience and proven methodology. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of research and expertise. For more information, please visit the website at www.gubra.dk.